Literature DB >> 18049889

The effects of GnRH antagonist on the endometrium of normally menstruating women.

Porntip Sirayapiwat1, Somchai Suwajanakorn, Surang Triratanachat, Somchai Niruthisard.   

Abstract

PURPOSE: To study the effects of GnRH antagonist (ganirelix-Orgalutran) on the endometrium of regularly menstruating women.
MATERIALS AND METHODS: Prospective, self-controlled study. The thirty-five volunteers were studied for two cycles: one as a control and the other, GnRH antagonist-treated cycles in which ganirelix 0.25 mg/d was given daily for 3 days, starting when the largest follicle reached 15 mm. In both cycles, serum estradiol, LH and endometrial thickness were measured when the largest follicle was > or =18 mm. Endometrial biopsy was performed on day 6 after ovulation for histological dating and morphometric study.
RESULTS: No statistical differences between histological dating and the endometrial thickness in the control and GnRH antagonist-treated cycles. All morphometric parameters were also not different. Serum estradiol and LH levels were significantly lower in GnRH antagonist-treated cycles.
CONCLUSION: GnRH antagonist has no effect on the endometrium of regularly menstruating women as assessed by either histological dating or morphometric analysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18049889      PMCID: PMC3455003          DOI: 10.1007/s10815-007-9184-z

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  36 in total

1.  Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers.

Authors:  J J Oberyé; B M Mannaerts; J A Huisman; C J Timmer
Journal:  Fertil Steril       Date:  1999-12       Impact factor: 7.329

2.  GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry.

Authors:  Georg Griesinger; Ricardo Felberbaum; Klaus Diedrich
Journal:  Hum Reprod       Date:  2005-06-02       Impact factor: 6.918

3.  Effects of clomiphene citrate on the endometrium of regularly cycling women.

Authors:  W Sereepapong; S Suwajanakorn; S Triratanachat; P Sampatanukul; K Pruksananonda; W Boonkasemsanti; D Reinprayoon
Journal:  Fertil Steril       Date:  2000-02       Impact factor: 7.329

4.  Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?

Authors:  Bart C J M Fauser; Paul Devroey
Journal:  Fertil Steril       Date:  2005-06       Impact factor: 7.329

Review 5.  Gonadotrophin-releasing hormone antagonists for assisted conception.

Authors:  H G Al-Inany; A M Abou-Setta; M Aboulghar
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

6.  Possible direct effect of gonadotropin releasing hormone on human endometrium and decidua.

Authors:  S Takeuchi; N Futamura; H Minoura; N Toyoda
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

7.  High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.

Authors:  S Kol; A Lightman; T Hillensjo; P Devroey; B Fauser; B Tarlatzis; B Mannaerts; J Itskovitz-Eldor
Journal:  Hum Reprod       Date:  1999-09       Impact factor: 6.918

8.  Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle.

Authors:  F Raga; E M Casañ; J S Kruessel; Y Wen; H Y Huang; C Nezhat; M L Polan
Journal:  Biol Reprod       Date:  1998-09       Impact factor: 4.285

9.  Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study.

Authors:  C Newton; D Slota; A A Yuzpe; I S Tummon
Journal:  Fertil Steril       Date:  1996-06       Impact factor: 7.329

10.  A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.

Authors: 
Journal:  Hum Reprod       Date:  1998-11       Impact factor: 6.918

View more
  2 in total

1.  Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol.

Authors:  Behnaz Khani Rabati; Setare Nasiri Zeidi
Journal:  J Res Med Sci       Date:  2012-11       Impact factor: 1.852

2.  Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol.

Authors:  Maryam Eftekhar; Razieh Dehghani Firouzabadi; Hesamoddin Karimi; Elham Rahmani
Journal:  Iran J Reprod Med       Date:  2012-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.